Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
KalVista Pharmaceuticals ( (KALV) ) has issued an update.
On April 29, 2026, KalVista Pharmaceuticals and Italy’s Chiesi Group signed a definitive merger agreement under which Chiesi will acquire KalVista via a tender offer at $27.00 per share in cash, valuing the equity at about $1.9 billion and representing a 36% premium to KalVista’s 30‑day VWAP. The transaction, unanimously approved by both boards and not subject to a financing condition, is expected to close in the third quarter of 2026 subject to a majority tender of shares and antitrust and other customary regulatory approvals.
Following completion, KalVista will become a wholly owned subsidiary of Chiesi, which will assume responsibility for EKTERLY (sebetralstat), the first oral, on‑demand therapy for hereditary angioedema, already showing strong early uptake with $49 million in 2025 sales. The deal marks Chiesi’s largest acquisition to date and is intended to significantly expand its rare immunology franchise, U.S. commercial footprint and progress toward its 2030 revenue target, while delivering an immediate all‑cash exit for KalVista shareholders and potentially accelerating global patient access to sebetralstat.
The most recent analyst rating on (KALV) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
The score is held back primarily by weak financial fundamentals (large losses, heavy cash burn, and a strained balance sheet with negative equity), despite strong technical momentum and a positive corporate update indicating accelerating product uptake and expanding commercialization.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for rare diseases, with a key emphasis on hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), is a novel oral, on‑demand plasma kallikrein inhibitor for treatment of acute HAE attacks in patients aged 12 and older, commercially launched in major markets including the U.S., U.K., EU and Japan.
Average Trading Volume: 982,039
Technical Sentiment Signal: Buy
Current Market Cap: $981.4M
For a thorough assessment of KALV stock, go to TipRanks’ Stock Analysis page.